Biologic rationale and evidence for high-dose hydroxocobalamin in septic shock

Area of Science:

• Critical care medicine
• Pharmacology
• Biochemistry

Background:

• Sepsis triggers an inflammatory response, increasing gasotransmitters (nitric oxide, hydrogen sulfide) that contribute to septic shock.
• Current sepsis treatments do not address these gasotransmitters.
• Hydroxocobalamin (HOC) is an intervention that targets circulating gasotransmitters.

Purpose of the Study:

• Review the role of gasotransmitters in septic shock.
• Outline the rationale for using high-dose HOC in septic shock.
• Summarize clinical evidence for high-dose HOC in septic shock.

Main Methods:

• Review of preclinical studies on HOC in septic shock models.
• Analysis of case series and Phase IIa clinical trial data.
• Examination of existing clinical evidence for high-dose HOC efficacy and safety.

Main Results:

• Elevated nitric oxide and hydrogen sulfide in early septic shock correlate with disease severity.
• Preclinical data show HOC improves outcomes by scavenging these gasotransmitters.
• Clinical studies indicate high-dose HOC is safe and reduces vasopressor needs in adults with septic shock.

Conclusions:

• High-dose HOC is a safe, nontoxic intervention targeting a key septic shock pathway.
• Observational and Phase IIa data are compelling.
• A pivotal Phase III trial is necessary before recommending widespread use.